Intellectual property

Mucosis considers patents and proprietary know-how to be critical assets of our company. We protect our scientific findings and inventions by filing patents in all major markets in America, Europe and Asia and by keeping non-patentable know how as trade secret. Our Mimopath® technology is broadly protected by a number of patents families that include over 20 granted and in-process patents. Moreover, we’ve registered numerous trademarks for our technology and products.

coherent strong patent portfolio

15.11.11 Mucosis announces new scientific advisory board
more >

17.05.11 Mucosis appoints Thomas Johnston as Chief Business Officer
more >

21.03.11 Mucosis starts clinical study with its lead product, Flugem®
more >

12.11.10 Dr. Barry Buckland joins the Mucosis supervisory board
more >

28.09.10 Mucosis B.V. and PATH sign agreement to pursue Mimopath®-based oral diarrhea vaccines
more >